CULLINAN THERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
CULLINAN THERAPEUTICS, INC. (CGEM) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$1.43 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$2.09M.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $662.00K.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$840.00K, a 151.38% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$798.00K.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$6.90M, a 379.00% decline from fiscal 2024.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $2.47M, a 58.41% decline from fiscal 2023.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $5.94M, a 426.02% increase from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $1.13M, a 65.43% decline from fiscal 2021.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.43M 10-Q · filed 2026-08-06 | -$2.27M derived: sum of 3 quarters · filed 2026-08-06 | -$3.06M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $662.00K 10-Q · filed 2026-05-07 | -$178.00K derived: sum of 2 quarters · filed 2026-05-07 | -$976.00K derived: sum of 3 quarters · filed 2026-05-07 | -$4.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$840.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | -$1.64M derived: sum of 2 quarters · filed 2026-03-10 | -$5.16M derived: sum of 3 quarters · filed 2026-08-06 | -$6.90M 10-K · filed 2026-03-10 |
| 2025-09-30 | -$798.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$4.32M derived: sum of 2 quarters · filed 2026-08-06 | -$6.06M 10-Q · filed 2025-11-06 | -$4.42M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$3.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.26M 10-Q · filed 2026-08-06 | -$3.62M derived: sum of 3 quarters · filed 2026-08-06 | -$4.97M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$1.74M 10-Q · filed 2026-05-07 | -$107.00K derived: sum of 2 quarters · filed 2026-05-07 | -$1.45M derived: sum of 3 quarters · filed 2026-05-07 | $1.14M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $1.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $291.00K derived: sum of 2 quarters · filed 2026-03-10 | $2.88M derived: sum of 3 quarters · filed 2026-03-10 | $2.47M 10-K · filed 2026-03-10 |
| 2024-09-30 | -$1.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.25M derived: sum of 2 quarters · filed 2025-11-06 | $837.00K 10-Q · filed 2025-11-06 | $4.13M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.18M 10-Q · filed 2025-08-07 | $5.47M derived: sum of 3 quarters · filed 2025-08-07 | $9.29M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$411.00K 10-Q · filed 2025-05-08 | $2.88M derived: sum of 2 quarters · filed 2025-05-08 | $6.69M derived: sum of 3 quarters · filed 2025-05-08 | $4.78M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $3.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $7.11M derived: sum of 2 quarters · filed 2025-02-27 | $5.19M derived: sum of 3 quarters · filed 2025-02-27 | $5.94M 10-K · filed 2025-02-27 |
| 2023-09-30 | $3.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.90M derived: sum of 2 quarters · filed 2024-11-07 | $2.65M 10-Q · filed 2024-11-07 | $3.27M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$1.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$1.16M 10-Q · filed 2024-08-08 | -$538.00K derived: sum of 3 quarters · filed 2024-08-08 | -$1.08M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $755.00K 10-Q · filed 2024-05-15 | $1.38M derived: sum of 2 quarters · filed 2024-05-15 | $835.00K derived: sum of 3 quarters · filed 2024-05-15 | $745.00K derived: sum of 4 quarters · filed 2024-05-15 |
| 2022-12-31 | $623.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $80.00K derived: sum of 2 quarters · filed 2024-03-14 | -$10.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.13M 10-K · filed 2024-03-14 |
| 2022-09-30 | -$543.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$633.00K derived: sum of 2 quarters · filed 2023-11-08 | $507.00K 10-Q · filed 2023-11-08 | -$1.33M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$90.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $1.05M 10-Q · filed 2023-08-10 | -$785.00K derived: sum of 3 quarters · filed 2023-08-10 | -$880.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $1.14M 10-Q · filed 2023-05-11 | -$695.00K derived: sum of 2 quarters · filed 2023-05-11 | -$790.00K derived: sum of 3 quarters · filed 2023-05-11 | $57.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$1.93M derived: sum of 2 quarters · filed 2023-03-09 | -$1.08M derived: sum of 3 quarters · filed 2023-03-09 | $3.27M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$95.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $752.00K derived: sum of 2 quarters · filed 2022-11-14 | $5.10M 10-Q · filed 2022-11-14 | $5.04M derived: sum of 4 quarters · filed 2022-11-14 |
| 2021-06-30 | $847.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $5.20M 10-Q · filed 2022-08-10 | $5.13M derived: sum of 3 quarters · filed 2022-08-10 | $5.58M derived: sum of 4 quarters · filed 2022-08-10 |
| 2021-03-31 | $4.35M 10-Q · filed 2022-05-16 | $4.29M derived: sum of 2 quarters · filed 2022-05-16 | $4.74M derived: sum of 3 quarters · filed 2022-05-16 | $5.51M derived: sum of 4 quarters · filed 2022-05-16 |
| 2020-12-31 | -$64.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $386.00K derived: sum of 2 quarters · filed 2022-03-17 | $1.16M derived: sum of 3 quarters · filed 2022-03-17 | $462.00K 10-K · filed 2022-03-17 |
| 2020-09-30 | $450.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $1.22M derived: sum of 2 quarters · filed 2021-11-09 | $526.00K 10-Q · filed 2021-11-09 | |
| 2020-06-30 | $769.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $76.00K 10-Q · filed 2021-08-10 | ||
| 2020-03-31 | -$693.00K 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |